NCE-1 Intelligence & Market Opportunity

Cabenuva

Cabotegravir And Rilpivirine (Co-Packaged)

Antiviral

Intramuscular Suspension, Extended Release

Approval Date

21-Jan-21

NCE-1 Date

21-Jan-25

NCE Date

21-Jan-26

Commercial snapshot

Market performance & projections

Revenue ($M)

1847

CAGR (%)

0.1361

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2243

2027

2577

2028

2928

2029

3077

2030

3218

2031

2861

2032

2610

Molecule profile

Details & specifications

Molecule

Cabotegravir And Rilpivirine (Co-Packaged)

Innovator

VIIV HEALTHCARE COMPANY

Dosage Form

Intramuscular Suspension, Extended Release

Strength

400 mg/2 mL (200 mg/mL), 600 mg/3 mL (200 mg/mL)

Therapeutic Category

Antiviral

Usage

To treat HIV

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.